Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Ernexa Therapeutics Inc.: Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development | 2 | GlobeNewswire (USA) | ||
Di | Ernexa Therapeutics completes second closing of securities offering | 1 | Investing.com | ||
Di | Ernexa Therapeutics Inc.: Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement | 1 | GlobeNewswire (USA) | ||
12.06. | Ernexa Therapeutics kündigt Aktienzusammenlegung im Verhältnis 1:15 an | 3 | Investing.com Deutsch | ||
11.06. | Ernexa Therapeutics registers 57M shares for resale | 2 | Seeking Alpha | ||
11.06. | Ernexa Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
10.06. | Ernexa Announces 1-for-15 Reverse Stock Split Effective June 12 To Regain Nasdaq Compliance | - | RTTNews | ||
ERNEXA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
10.06. | Ernexa Therapeutics announces 1-for-15 reverse stock split | 1 | Investing.com | ||
10.06. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split | 167 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced... ► Artikel lesen | |
09.06. | Ernexa Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
02.06. | Ernexa Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
28.05. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025 | 2 | GlobeNewswire (USA) | ||
14.05. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations | 118 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced... ► Artikel lesen | |
08.05. | D.Boral Capital: Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference | 234 | Newsfile | Cambridge, Massachusetts--(Newsfile Corp. - May 8, 2025) - Ernexa Therapeutics (NASDAQ: ERNA), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May... ► Artikel lesen | |
07.05. | Ernexa Therapeutics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
29.04. | Ernexa reports promising cancer cell therapy study results | 2 | Investing.com | ||
22.04. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025 | 1 | GlobeNewswire (USA) | ||
03.04. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Closes New Funding Round | 160 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced... ► Artikel lesen | |
03.04. | Eterna Therapeutics Inc. - 8-K, Current Report | 5 | SEC Filings | ||
25.03. | Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease | 120 | GlobeNewswire (Europe) | Ernexa Therapeutics embarks on new strategic direction, shifting the company's focus from delivering a cell therapy platform to prioritizing product development New tagline to emphasize the company's... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PALATIN TECHNOLOGIES | 0,120 | -1,64 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
BIOXXMED | 0,480 | +17,07 % | EQS-News: bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024 | EQS-News: bioXXmed AG
/ Schlagwort(e): Jahresbericht
bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024
27.06.2025 /... ► Artikel lesen | |
VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
OCUGEN | 0,858 | -1,06 % | Ocugen, Inc.: Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases | Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform... ► Artikel lesen | |
SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
BIO-GATE | 0,880 | -10,66 % | Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | Nürnberg (www.anleihencheck.de) - Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts - AnleihenewsVorstand und Aufsichtsrat der Bio-Gate AG (ISIN DE000BGAG981/... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,470 | +2,17 % | Defence Therapeutics Inc.: Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology | Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
VAXART | 0,433 | +2,90 % | Vaxart, Inc.: Vaxart Announces Preliminary Results of Annual Meeting of Stockholders | SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen | |
BURCON NUTRASCIENCE | 2,635 | +1,54 % | Burcon NutraScience Corporation: Burcon Announces Fiscal 2025 Results and Reviews Operations | Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
CELLECTAR BIOSCIENCES | 7,940 | +7,59 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA39261L2049 Green Battery Minerals Inc. 23.06.2025 CA3194101067 First Canadian Grahite Inc. 24.06.2025 Tausch 1:1US15117F8077 Cellectar... ► Artikel lesen | |
AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
AIM IMMUNOTECH | 7,700 | 0,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements | NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025 AIM has until June 11, 2026 to regain compliance OCALA... ► Artikel lesen | |
IMMUNIC | 0,602 | +1,01 % | EQS-News: Immunic AG: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis | Issuer: Immunic AG
/ Key word(s): Study/Study results
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in... ► Artikel lesen | |
T2 BIOSYSTEMS | 0,096 | +1,49 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
CEL-SCI | 2,410 | -1,83 % | Pre-market Movers: Navitas Semiconductor, Longevity Health, CEL-SCI, Hyperscale Data, Sunrun | PHILADELPHIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 06.35 A.M. ET).In the Green Navitas Semiconductor Corporation (NVTS) is... ► Artikel lesen |